INDIANAPOLIS, Aug. 20 (UPI) -- Indianapolis pharmaceutical giant Eli Lilly went on a shopping spree Wednesday, closing one major deal and reaching a purchase agreement for Posilac.
SGX Pharmaceuticals Inc. (
Nasdaq: SGXP) will be acquired by Eli Lilly & Co. (
NYSE: LLY) for approximately $64 million. Shares of SGX leaped $1.69 to $3.06 while Eli Lilly stock rose 87 cent to $49.33....
We are keeping our Buy recommendation on Companhia de Saneamento Basico do Estado de S?o Paulo, or SABESP (SBS). The company posted positive results for the second quarter of 2008, even though operating margins were lower. Net operating revenues reached R[More...]
A 6-Page Stock Profile for YMI is Now Available to View or Download as a PDF at www.geocities.com/mikehavrx/YMI.pdf While the market is focused on just the pending colorectal cancer trial data; it ignores several major points on YM BioSciences:(1) the ...
On July 9, Eli Lilly (LLY) announced the decision to acquire all outstanding shares of SGX Pharmaceuticals Inc (SGXP) at $3 per share. SGX shifted its focus to the FAST programs after the discontinuation of its only candidate Troxatyl for third-line acute
[More...]
SGX Pharma (
Nasdaq: SGXP) 6-Month Chart Shares of SGX Pharma (SGXP) soared after hours Tuesday on news of an all-cash $64 million buyout from Eli Lilly (LLY). The buyout represented a premium of more than 100% at $3 per share for SGX, which is being ac...
Shanda Interactive's (SNDA) revenue and earnings for the fourth quarter showed strong growth, which exceeded market expectations. We think Shanda's results demonstrate the strengths of its item-based revenue model and its comprehensive operating platform,
[More...]
Andrew Coffey and Steve from Knobias research talk about:
"Trading the 08' election" and 2006 IPO's that have been knocked down like PXPL, VG, REST, ATEC, SGXP and NCST.
Special Conference
SGX PHARMACEUTICALS INC at BioCentury Publications Inc./Thomson Financial: Future Leaders in the Biotech Industry Conference
Archive for SGXP